Studies sbow that tbe timing of tbronkiy:ic tberapy is a major factor in determining the magnitude rit the mortality reduction with tbesc ageots in the treatment of acute myoeardiaI infarction (l-3). Although tbe survival benefit from tbrombolysis persists with admhdstratioo up to 12 b aber symptom onset, the largest t%ect is observed wben treatmeot begins witbin tbe litst hour, with attenuation of the treatnmot benefit over time (4). These dinieal observations are consistent with animal IaagefdeIaysatatls(ages.I%viousinlsrrtiooarhypasssugerS was an a&litiortaI risk hwtor for treatment delay. Early tImtobaIysIswasasaaciatedwlthhnreraveraIImortaHyrate(e2b, 559b>4B,9~),Batseaddi~relativoBeaefttrrsnlted~ ediir batmeat wits acdemted t-PA wrws sqtokkw (p = 038).LQ3gerpresmt3tion3ntltreatmeotdel3yswereb3tJl3sso. rioted witb ilwmsed ltmrmty me (present3tkm dehy <I 4 5.6%6968wl4$lw& tr&dmmdclay<lB,5.4%,asd*~oris, o.l%).A3timetotre3t3lentiaaeaeed,theiFtddeoreofrecmvent iSCkeEtitt~~dmPPse&bOttbenrtesdS8aek,hoart bihue3nd3tmke-models of acute coronary occlusion, wbiib show that restoration of arterial patency witbin 1 to 2 h sahages myoeardium and pffscfvcs veotriethr limction (5). AIthough many trials have shown better improvement in left ventricular function and limitatioo of infarct size with very eatiy treattneot (69), none of the large mortality trials have achmlly mllected the to treatment. They &owed a sign&cant reIation of time to randomization to treatment effect (2,10-12), but exchtsion of the variable time from randomktion to treatment may bave rcstdtcd in a0 imprecise estimate. of the @ortamx of delay. In addition the relatiins between patient characteristics and delay in seeking treatmeot (preseotation deiay) and deIa: in initiating tbrornboIysis after bospkal arrival (treatment jelay) bave Lee0 of interest, but Iitnited sample sizes in indiviouaI studies bave led to &abibty in the estimate of factors associated with these delays (13) .
Using the 41,021 patieots in tlte GUSTO-I trial, we examined patient characteristics as they relate to time-totreatment variables and amessed the reIations between time to treatment and its major eompooents, preseotatior delay aod treatrnett delay, and tbe r&h of death. We also ,xatn-
tissue-type plasminogen activator (t-PA) versus two streptokinase monotherapies.
Methods
Patient popnh~tio~~ The 41,021 patients in GCSTW cornprised our study population.
Complete methods of the trial have been published (14) . In brief, patients were randomized to one of four thrombolytk treatments if they presented within 6 h of symptom onset (minimum duration 20 min), met eledrocardiiphic criteria for acute myxirdial infarction (~0.1 mV ST elevation in two or more limb leads or ~0.2 mV ST elevation in at least two contiguous precordial leads) and had no contraindiitions to thrombolysis. Time variahks.
For this study, three time variables were prospectively defined: time from symptom orrset to hospital arrival (presentation delay), time from hospital arrival to initiation of thrombolytic therapy (treatment delay), and total time from symptom onset to rhromboiytic therapy. The patient (or a surrogate if the patient could not communicate) provided the time of onset of symptoms resulting in hospital presentation. Time of hospital arrival and time of thromboiysis (initi&on of infusion) were obtained from hospital records.
Before publication of thii manuscript, an extensive qualitycontroi etrort was completed that resulted in some changes in the data published in the initial report of GUSTO-I (14) (15) (16) M-day and in-h<npital mortality, srrokr \&types, reinfatction, recurrent itihemta. shock. and congey(ne heart failure and the combined end pomtu 01 death or \trokc. deurh or primary intracranirl hemorrhage and death or disabling ~lroke.
Results
Time ta treatment.
Complctc data for time from qmptom onset 10 thrornboiysis were available for 39.KG of the JI,K!I patients tU7.15 ). C'umulalive dLributions of rime Lo treat. mcnt overall and by enrollment site (Uniled Slatir versus nonJ.~m~ed SMCS) are shown in f:igure I. Overall time to trcatn cnl was --4 h in 77.4% of patients; most of the rest were lreiiled between 4 and 6 b &iy 26.6% of patients were IrCdtCd uithin 2 h of symptom onset.
Riixline characlerlstics by time from stziptom onset to treatment are shown in Table 2 . Female, hypertensive. and cbabetic patients were found in greater proportions in tile later-treated group, and current or former cigarette .srnoken werr more often in ibe earlier-treated groups. Prior myoma:. ). The pmbability for the combined streptekinase gruups is show0 by tbe bemy solid hue dial infarction was more frequent in the later-treated groups, and patients treated after 2 h were older, weighca less, had higher systolic blood pressures and heart rates and were more likely to be nonwhite and to have congestive hedrl failure (Killip class 41). Other than a slight delay (median 5 mm) in patients treated with combination thromholytic therapy, there were no differences in time to treatment as a function of treatment assignment. strategy as a function of time from symptom onset to treatment. Although the relative treatment effect was slightly greater for patients treated earlier, the formal test for time-totreatment interaction for t-PA versus !he combined streptokinase groups was not significant (p = 0.38). Table 3 shows the relations between time to treatment and selected clinical end points. As time to treatment increased, 3O-day mortality increased (Fig. 2) . The incidence of stroke also increased as time to treatment increased, mostly through an increase in primary intracranial hemorrhage. Reinfarction and recurrent ischemia were less frequent, and the incidence of shock and congestive heart failure greater, as time to treatment increased. Table 4 . The distribution of baseline characteristics was similar to that for the total-time-totreatment group. However, patients with a family history of 
Dkcussion
This evaluation of the 41,021 GUSTO-I patients shows that substantial differences in baseline characteristics and outcomes exist between patients who pursue and receive thrombolysis promptly and those whose treaunent is delayed. Further, although a trend is present, the relative reduction in mortality from accelerated t-PA treatment is not signitkantiy a&ted by this delay. Most characteristics associated with longer presentation delay are also associated with longer treatment delay, raising the possibility that focusing attention on female, elderly, diabetic and more critically ill patients can greatly improve outcomes by reducing time to treatment.
Time to treatment. Defined as time from symptom onset to initiation of infusion, !ime to treamlent provides an estimate of the total time of vessel occlusion.
Accurate assessment of treatment effect as a function of time is ditlicult, however, because the measurement of time to treatment is inherently imprecise; time of symptom onset and time of thrombtrbtic Flgwa 5. Cumulative distribution of time frwn hospital arrival to treatment overall (s&l Hne) and for patients enrolkd in the United States (tuq dart& and ouaide the United States (short &she@.
initiation do not correlate exactly with the relevant eventsvessel occlusion und reperfusi&, respectively. Further, the variable time to treatment does not capture the additional time from thrombolytic initiation to reperfusii nor is infarctartery patency achieved in each case. Indeed, when w reperfusiin oszurs 45 to 60 min after initiation of tluombolytic therapy (17.18) .
In GUSTO-I, the median time to treatment was 2.8 h, similar to that seen in actual practice (median 2.75 h) during the sane time period, as suggested by comparkm with data from the National Registry of Myocardii Infarction (NRMI) survey (19) . To better assem risk factors for this delav in treatment, we prospe&eiy divided overall delay into two components: presentation delay, which reikcts patient-related delays, and treatment delay, which rekcts the response of hospitals to patients. l3wenUon a'day. Studies show that presentation delay accounts for the greater proportion o! total time to treatment (20,21). The median presentation delay in GUSTO-l was 92 minutes, 55% of total time to treatment. Studies suwt that patients tak.e much of this time to decide to xeit medical treatment f 13,20-24). Many facton have been shown to alfect this decision, including time of day, day of the week, location of the patient when symptoms occur, symptom severity or typicality and whether advice is sought from co-workem, family members or the family physiian (13,X23,25-27 ). Our analysis, based on over 41,000 patients, adds substantial information and clarification to smaller. less detailed 0bwations (13,1tU&2829) . It supports the fin+ng that advanced age, diabetes, hypertension and prior angina are indeed risk factors for presentation delay, as is female gender. Contrary to pmvious stud& we noted an association between earlier presentation and prior infarction or family history Of coronary dii.
Further. there WBS no relation of race to presentation delay. Ahbough median bkmd pressure was iower in the groups presentis@ earlier, other marken of a complicated infarction-faster heart rate and higher Killip class- Table 2. were associated with longer prewntalion dcluy in GUSTO-I. Table 8 bumrnatizcs Ihcse comparisons. Trrtr~cnr Crclq In GUSTO~I, the median rrcatment delay was 64 min. Little information exists regarding the relation of baseline characteriprics to treatment delay. One study Cd show that the degree of ST segment deviallon on irtitial clecttocatdiograpby wa importint (30). In out study, most chatsctct~~ tics asmiated with longer presentation delay were also as* ctlrtrd with longer treatment &lay. Nonwh me race was assuciatcd +I& with longer treatment &lay <,:,), ~texWtii+l del.*y). la addition, pnot bypa~ surgery end previous infarction, whir.n were tiated with no etiect on and Wet prcscntation delays. respectively, were associated with longer treatment delay. Groups with longer treatment delays were those whose initial symptoms are mote likely atypical (women, diabetics, the elderly) or for whom the benefit relative to the risks of thtombolysis ate uncertain (the elderly, hypertensive+ Although differences existed in the distribution of electtocatdiogtaphic variables (othct than infarct location) hctwecn earlier-and later-treated patients, these were small and unlikely to be of major clinical significance (Tabks 2.4 and 6).
Time to treatwst-trportmce d tieby to dlnlcal witcamea. The Fibrinolyiic Therapy Trial&s' meta-analysii su8 ge5ted that outcome was significantly better with shorlct time from symptom onset (I.6 additional lives saved per I.000 treated for each hour earlier that tteatmenl began) (I). The absolute and relative treatment effects for therapy 1 h earlier were greater the earlier treatment began, presumably reflecting the important time-dependent effect of vessel occlusion on the extent of irreversible myocardial damage. Similarly in GUSTO-I, independent of thrombolytic assignment, delays at any point adversely affected mortality and the development of heart failure or shock. underscoring the importance of early recognition of and response to ischemic symptoms. Although stroke, mostly hemorrhagic, seemed to increase with increased time to treatment, a multivariable analysis of stroke risk factors in GUSTO-I found no relation with time to treatment (31). Overall mortality increased as time to treatment increased, but patients treated very early (Cl h) after symptom onset T&e 8. Association of Eiascliw Characteristics With Presentation Delay: Compnriwn of Prcwus Reports With GUSTO-I appeared to have higher mortality than those treated between l-;nd 3 h (Fig. 2) . It may be that patients who present and are treated very early are sieker, with a higher expected mortality. The small number of patients treated within I h may have limited the ability to detect a difference in severity of illness between these groups. Further, patients with acute myocardial infarction have the greatest risk of lethal ventricular arrhythmias during the first hour of symptoms. Perhapr the higher mortality observed in patients with a shorter time to thrombolysis simply reflects this pathophysiology.
Finally, the smell size of the group treated within I h and the wide 95% contidcnce intervals suggest that caution should be used in interpreting tkese results. &cause presentation delay primarily reflects patient response to symptoms. public education programs have been the main focus for its improvement.
To date, mass-media campaigns and public education programs have had variable results in improving presentation delay (32) (33) (34) (35) . Programs and services focused on groups idendtied as being at highest risk for presentation delay may be mare helpful. Because it reflects the medical system reapon% to patients, time to treatment may be most easily decreased through procedurai and diagnostic strategies focused on treatment delay. Institution of specific emergency room protocols can significantly reduce treatment <clay (2X36-31). as can administration of thrombolysis by emergency room physicians without mandatory cardiology consultation (25) . arrival by ambulance (22) and transmission of an initial electrocardiogram from the ficld (39.40) .
Tlme lo tmlnsesldtalefl L-P.4 vcIM)s Olrrpkokll4n~* The GUSTO-1 investigaton postulated that more rapid repetfusion with accrlerated t-PA would result in proportionately more mytrcardial salvage in patients treated early and would be reflected& a greater survival advantage in these patients. The original G!'STO-I report noted an apparent interaction betwecn earlier treatment with accelerated t-PA and a yeater relative \urvivrl benefit (11) . However, after careful quality-control measures, the trend toward a greater survival benctil with accclcrated I-PA in patients treated early did not reach statistical significance (15.16). This result may emanate from hvo major factors: the timing of symptom onset is not precisely related to the initial coronary occlusion, and hecause patients with longer times to treatment are generally sicker (with a higher expected mortality), they therefore have a greater mathematical opportunity for clinical benefit, although pathophysiologically their chances for benefit are less. Several statistical issues regarding thii finding also must be addressed. Fit, because the analysts for treatment interaction uses time to treatment as a continuous variable, the relatively few (4,825) changes in data that resulted from the quality-control process, although not altering the shape of the data, were sufficient in this setting to change a borderline statistically significant result (p -0.04) to a, nonsignificant one (p = 0.38). Further, for the comparison of t-PA versus the combined streptokinase stratcgies, post hoc analysis shows that the power of the test for an interaction of treatment effect with time to treatment is only about 0.18. However, with a sample si-e of river 40,000 patients for the overall analysis, the p value ot 0.38 Indicates strong evidence of no differential effect rather than a lack of power to detect a difference. Although the relative benefit from t-PA in the first hour seems greater, as does that for the combination therapy after 5 h, the number of patients in each group at these intervals was small, precluding any definitive statements about these observations.
Concbtsians. Although imprecision in measurement may limit our ability to detect subtle time-dependent treatment ekcts somewhat, we found no additional relative advantage for earlier treatment with accelerated t-PA versus streptokinase, although a trend was present. Regardless of the agent, earlier thrombolysis resulted in better outcomes, with the best effects for treatment within 2 h of symptom onset. Focused educational, diagnostic and management strategies to facilitate early identification and rapid treatment, especially of those at high risk for delay, should help maximire the benefits of thmmbolytic therapy.
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